Coral Laboratories FY26 Results: Revenue and Profit Decline, Cash Flow Improves

Coral Laboratories Ltd reported its audited financial results for the fiscal year ended March 31, 2026, revealing a contraction in both revenue and net profit.

Revenue from operations for FY26 stood at ₹85.90 crore, a decrease of approximately 25% from ₹115.01 crore in FY25. Net profit also saw a significant decline, falling by about 32% to ₹16.38 crore in FY26, down from ₹24.16 crore in the previous year. Basic Earnings Per Share (EPS) consequently dropped to ₹45.85 from ₹67.61.

Reader Takeaway: Revenue and profit contraction is a concern, but improved operating cash flow offers some respite.

What just happened

Coral Laboratories announced its audited financial results for the fiscal year 2025-2026. The company reported a revenue of ₹85.90 crore and a net profit of ₹16.38 crore for FY26. This marks a decrease compared to the ₹115.01 crore revenue and ₹24.16 crore net profit recorded in FY25.

The company's net profit saw a steeper decline of approximately 32% than its revenue, which fell by about 25%. This suggests potential pressure on the company's profit margins during the period.

Why this matters

For investors, the decline in revenue and profit indicates a challenging business environment or internal operational issues impacting the company's top and bottom lines. The steeper fall in profit compared to revenue points to margin compression, which needs to be closely watched. However, a significant improvement in operating cash flow from a negative ₹1.22 crore in FY25 to a positive ₹15.62 crore in FY26 is a positive sign, suggesting better working capital management and operational efficiency in converting sales to cash.

The board's recommendation of a final dividend of ₹2.00 per share indicates management's confidence in the company's financial health and ability to reward shareholders, even amidst the downturn.

The backstory

Coral Laboratories Ltd is a pharmaceutical company engaged in the manufacturing and marketing of various pharmaceutical products. The company operates in a competitive industry, and its financial performance is subject to market dynamics, regulatory changes, and raw material costs.

What changes now

The reported financials will be a key point of discussion for investors. The focus will shift to management's strategy to reverse the declining trend in revenue and profit and improve operational efficiency. The positive cash flow generation could provide the company with financial flexibility for future growth initiatives or to weather market challenges.

Risks to watch

The primary risk for Coral Laboratories is the continuation of the revenue contraction and margin pressure. The company needs to demonstrate its ability to regain market share or improve sales volumes. Investors will also monitor the effectiveness of the newly appointed internal and cost auditors in ensuring robust financial governance.

Peer comparison

While specific peer financial data for FY26 is not provided in the filing, the general pharmaceutical sector in India has faced mixed performance due to pricing pressures, competition, and evolving regulatory landscapes. Companies like Ajanta Pharma, Sun Pharma, and Cipla have also reported varying results, with some showing growth while others face challenges. Coral's performance needs to be viewed against these broader industry trends.

Context metrics (time-bound)

• Revenue from Operations: ₹85.90 crore (FY26) vs ₹115.01 crore (FY25) - a ~25% decrease.
• Net Profit: ₹16.38 crore (FY26) vs ₹24.16 crore (FY25) - a ~32% decrease.
• Operating Cash Flow: ₹15.62 crore (FY26) vs -₹1.22 crore (FY25) - a significant improvement.
• Dividend Recommendation: ₹2.00 per share for FY26.

What to track next

Investors should closely track Coral Laboratories' quarterly results for FY27 to observe any signs of revenue recovery and margin improvement. Management commentary on the factors driving the FY26 decline and their plans for future growth will be crucial. The company's ability to maintain positive operating cash flow and its dividend payout policy will also be key indicators.